SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:1SXP • DE000A3ENQ51
14.36 EUR
-0.02 (-0.14%)
Last: Jan 30, 2026, 07:00 PM
Taking everything into account, 1SXP scores 6 out of 10 in our fundamental rating. 1SXP was compared to 18 industry peers in the Life Sciences Tools & Services industry. 1SXP scores excellent on profitability, but there are some minor concerns on its financial health. 1SXP is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- 1SXP had positive earnings in the past year.
- In the past year 1SXP had a positive cash flow from operations.
- Each year in the past 5 years 1SXP has been profitable.
- In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 9.16%, 1SXP belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
- 1SXP has a better Return On Equity (16.42%) than 86.36% of its industry peers.
- With an excellent Return On Invested Capital value of 13.06%, 1SXP belongs to the best of the industry, outperforming 86.36% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for 1SXP is above the industry average of 9.98%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.16% | ||
| ROE | 16.42% | ||
| ROIC | 13.06% |
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1.3 Margins
- The Profit Margin of 1SXP (14.85%) is better than 72.73% of its industry peers.
- 1SXP's Profit Margin has improved in the last couple of years.
- Looking at the Operating Margin, with a value of 18.95%, 1SXP is in the better half of the industry, outperforming 77.27% of the companies in the same industry.
- In the last couple of years the Operating Margin of 1SXP has grown nicely.
- 1SXP has a worse Gross Margin (33.71%) than 68.18% of its industry peers.
- In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 14.85% | ||
| GM | 33.71% |
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1SXP is creating some value.
- The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
- Compared to 5 years ago, 1SXP has about the same amount of shares outstanding.
- The debt/assets ratio for 1SXP has been reduced compared to a year ago.
2.2 Solvency
- 1SXP has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as 1SXP would need 2.43 years to pay back of all of its debts.
- The Debt to FCF ratio of 1SXP (2.43) is better than 90.91% of its industry peers.
- A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
- 1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | N/A |
ROIC/WACC1.36
WACC9.58%
2.3 Liquidity
- A Current Ratio of 1.50 indicates that 1SXP should not have too much problems paying its short term obligations.
- The Current ratio of 1SXP (1.50) is better than 63.64% of its industry peers.
- 1SXP has a Quick Ratio of 1.12. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
- 1SXP has a Quick ratio (1.12) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- 1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.02%.
- 1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.78% yearly.
- The Revenue has been growing slightly by 3.04% in the past year.
- The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
3.2 Future
- Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.98% on average per year.
- 1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.13% yearly.
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y12.98%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 14.80, the valuation of 1SXP can be described as correct.
- Based on the Price/Earnings ratio, 1SXP is valued cheaper than 90.91% of the companies in the same industry.
- 1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 28.32, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 14.38 indicates a correct valuation of 1SXP.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 95.45% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.57, 1SXP is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.8 | ||
| Fwd PE | 14.38 |
4.2 Price Multiples
- 90.91% of the companies in the same industry are more expensive than 1SXP, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than 63.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.51 | ||
| EV/EBITDA | 8.27 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- 1SXP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)4.97
PEG (5Y)1.07
EPS Next 2Y8.11%
EPS Next 3Y9.33%
5. Dividend
5.1 Amount
- 1SXP has a Yearly Dividend Yield of 1.25%.
- The stock price of 1SXP dropped by -26.06% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
- Compared to an average industry Dividend Yield of 0.43, 1SXP pays a better dividend. On top of this 1SXP pays more dividend than 90.91% of the companies listed in the same industry.
- 1SXP's Dividend Yield is slightly below the S&P500 average, which is at 1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.25% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- 16.45% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.45%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status for 1SXP stock?
ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.
Can you provide the financial health for 1SXP stock?
The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 6 / 10.
What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?
The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 2.98% in the next year.